Biopool U.s., Inc.

Biopool U.S., Inc., doing business as Trinity Biotech Distribution, operates as a foreign-owned subsidiary of Ireland-based Trinity Biotech PLC and supplies clinical laboratory diagnostics equipment, hemoglobin A1c analyzers, and diagnostic test kits to federal healthcare agencies exclusively as a prime contractor — with no subcontract footprint in the source data. The company competes predominantly under full-and-open (non-set-aside) vehicles, though it holds one Total Small Business set-aside IDIQ with the Department of Veterans Affairs. Biopool is headquartered in Jamestown, New York, and maintains a manufacturer-and-distributor profile under primary NAICS codes for medical equipment wholesale (1,008 awards) and in-vitro diagnostic manufacturing (83 awards).

The vendor's federal customer base concentrates heavily in medical and healthcare logistics. The Defense Logistics Agency Troop Support Medical dominates by award count (1,041 awards, $9 million combined potential value) but issues predominantly small delivery orders for test kits and supplies. The Department of Veterans Affairs Veterans Health Administration splits across multiple VISNs, with VISN 12 anchoring the largest single dollar commitment ($9.7 million from four awards), followed by VISN 17 ($1.4 million from eight awards) and VISN 19 ($1.1 million from fifteen awards). The Department of Justice Medical Center for Federal Prisoners Springfield accounts for 16 awards ($737 thousand) and represents a sustained customer relationship built on annual BPA calls for hemoglobin A1c analyzers and clinical materials. These top five customers by either volume or dollars account for approximately 68% of recent awards and span 25% of combined potential value, indicating significant fragmentation across a broad federal healthcare procurement landscape.

Biopool holds five named indefinite delivery vehicles. A $4 million Federal Supply Schedule contract under Critical Analyzers, Laboratory (FSS-66-III), awarded July 15, 2024, running through July 14, 2029, offers hemoglobin A1c testing on a cost-per-reportable-result basis ($5.03 per test) to VA and other federal ordering activities, with a $100,000 maximum order value per transaction and 500-test-per-month minimum. A $50 million single-award BPA awarded February 6, 2024 (running through February 28, 2026) from the Office of Logistics and Acquisition Operations covers blood products, biological materials, medical equipment, and laboratory chemicals for VA, DLA, Department of Justice, and National Institutes of Health customers. The $199.5 thousand single-award BPA with the Medical Center for Federal Prisoners (October 1, 2023 through September 30, 2026) covers annual procurements of two hemoglobin A1c analyzers with clinical materials and services. A $170 thousand Total Small Business set-aside BPA with Veterans Integrated Service Network 19 (July 1, 2023 through June 30, 2027) covers hemoglobin A1c testing on a cost-per-reportable-result basis, with four annual calls issued ($34,000 to $40,254 per call). A $4 million Defense Logistics Agency Indefinite Delivery Contract under the SPE2DE program (October 12, 2021 through October 11, 2026) supplies laboratory reagents, diagnostics, and controls to DLA and federal medical facilities. Representative recent work includes a $77.6 thousand delivery order from Veterans Integrated Service Network 17 for hemoglobin A1c testing through August 2025, a $48.1 thousand BPA call modification with the Medical Center for Federal Prisoners for two hemoglobin A1c analyzers and clinical materials, and recurring monthly delivery orders from DLA for syphilis and glucose-6-phosphate dehydrogenase screening test kits, typically valued under $2,000 per order.

Activity remains steady at 11–18 awards per year over the past five years, with 1,638 total awards carrying $88.7 million in combined potential value. Only two awards totaling $46 thousand face completion in the next twenty-four months, indicating minimal recompete exposure in the near term. The vast majority of Biopool's work flows through the DLA Medical Capital Equipment Program (541 task orders, $142 thousand combined potential value) and older indefinite delivery contracts (SPM2DE11D7345, 383 task orders; V797P4087A Federal Supply Schedule, 174 task orders). Top product lines span Laboratory Equipment and Supplies (1,170 awards), In-Vitro Diagnostic Substances and Reagents (156 awards), and Medical and Surgical Instruments (111 awards), with particular depth in hemoglobin A1c testing equipment and associated clinical materials, syphilis and HIV test kits, and glucose-6-phosphate dehydrogenase controls and screening supplies.